Ultra Q - SLT-upgradeable, Nd: YAG Photodisruptor

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> PRODUCTS

Products	Ultra Q - SLT-upgradeable, Nd: YAG Photodisruptor
Company	Ellex (formerly Laserex)
Item	Ultra Q - SLT-upgradeable, Nd: YAG Photodisruptor
Features	Laser Type: Q-switched Nd:YAG Wavelength: 1064 nm Laser safety class: Class3B Energy selector: 0.3 to 10 mJ, single pulse continuously variable (<55 mJ maximum at triple pulse) Pulse width: 4 ns Burst mode: 1, 2 and 3 pulses per shot, selectable at 20 s separation Air breakdown: <2.8mJ* Mode structure: Fundamental, diffraction limited Spot size: 8 m Cone angle: 16 degrees Posterior offset: 100 m - 350 m, continuously variable Repetition rate: 2.3 Hz, single pulse*, 1.8 Hz, double pulse, 1.6 Hz, triple pulse Aiming beam: Semiconductor laser diode, continuous wave twin spot, 635 nm wavelength Laser delivery: Laserex slit lamp with Galilean type stereoscopic 16x microscope with converging optics Magnification: Three-position, detachable, 10x, 16x, 28x Safety filter: Fixed, colour-balanced Table dimensions: 445 mm x 920 mm Weight: 26 kg
Description	The Laserex Ultra Q is a hospital grade Nd: YAG laser photodisruptor system that provides ophthalmologists with a precise, reliable means for performing posterior capsulotomy, iridotomy and pupillary membranectomy. The system can be used for the treatment of secondary cataracts or opacification of the capsule (posterior capsulotomy), and closed-angle glaucoma (iridotomy). The Ultra Q is Laserexs flagship YAG laser, with its fully integrated Nd: YAG laser photodisruptor and in-built motorised stand. The systems integrated slit lamp design continues the Laserex tradition of leading edge integrated laser products. The unique slimline design and true ergonomics provide the benefits of ease of use coupled with patient-friendly features to fit all sizes. The Ultra Q provides more patient leg room, greater height adjustment range and an outboard chinrest all in the one package. The Ultra Q produces a 1064 nm wavelength treatment laser from a Q-switched Nd: YAG laser cavity located in the systems laser head housing. The major feature of the Ultra Q is its improved efficiency in producing tissue disruption. The systems lower air breakdown energy means that less energy is required to generate the same amount of disruption on the target tissue. This lower level of air breakdown energy dramatically reduces the incidence of IOL pitting; and this is especially important for silicone IOLs, which have a lower damage threshold. The Laserex Ultra Q is available in a Total Mobile stand or Total Access stand (wheelchair-accessible) configuration. Both stands are motorised for easy table height adjustment.
Info	Ellex (formerly Laserex) Customer Service: (800) 824-7444 Web site: http://us.ellex.com/

TAG: Ultra SLT upgradeable YAG Photodisruptor

...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...

Medicine Products:

Allergen, Food, Cherry Allergen, Food, Chicken Allergen, Food, Casein Allergen, Food, Blueberry

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...ST, the peer-reviewed journal of the American Coll...dietary intake of certain nutrients increases the ... especially in teens who smoke. Teenagers who for...e a harder time catching their breath. Furthermore...

...2007, issue of Neurology, the medical journal of t...ly Parkinsons disease report a higher than anticip...leepiness, and swelling. By identifying risk fact...isions, allow for early intervention and possibly ...

...mpaign to boost fruit and vegetable intake among y... Professor Janet Cade and colleagues of Leeds Un...nd Vegetable Scheme (SFVS), installed in 2004, on ... the north of England. A specially devised measure...

...therapy (HRT) should not be prescribed to older wo...ent chronic conditions such as heart disease . But...hort term treatment for younger women in early men...oms and improve quality of life. In 2002, the Wom...

Other Medicine News:Health News:Apple a Day Keeps Asthma Away 2 Health News:Apple a Day Keeps Asthma Away 3 Health News:Early Parkinsons Show Hallucination,sleepiness 2 Health News:Britains Free Fruit -And -Vegetable -Scheme Falls Flat 2 Health News:Study Confirms No HRT Benefit for Older Women 2 Health News:Study Confirms No HRT Benefit for Older Women 3

Apple a Day Keeps Asthma Away Early Parkinsons Show Hallucination,sleepiness Britains Free Fruit -And -Vegetable -Scheme Falls Flat Study Confirms No HRT Benefit for Older Women

(Date:8/17/2008)...- Pharmaxis,(ASX: PXS; Nasd...hase 3,clinical trial of Bronchitol for the treatm...The first efficacy data from the trial is expected...e trial commenced its dosing phase in,April 2007, ...ects in June,2008 and closed today with 325 subjec...

(Date:8/14/2008)... showing clinical benefit in cancer,patients; Blin... and attack cancer ce.../ -- Micromet, Inc.,(Nasdaq: MITI ), a biopharmac...bodies for the treatment of cancer, inflammation a...n of a Phase 1 clinical study(1) on its,BiTE(R) an...

(Date:8/13/2008)...all/ -- As biotechnology,pharmaceutical and medic...als beyond their own borders to other parts of the...rica, complicated regulatory environments,challeng...o an analysis by,Aon Corporation (NYSE: AOC ). Ao...ompanies a visual representation of the complex in...

(Date:8/13/2008).../ -- Today positron emission,tomography (PET) scan...gy,tool for diagnosis, staging and monitoring. It ...logy emitting a radioactive tracer to localize,tum...normal tissue. As a,result, the malignant tissue s... spot.", The use of multiple imaging technologies...

Breaking Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4 Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring? 2 Seeking sustainability in a world of instability 2198 1 Seeking sustainability in a world of instability 2198 2 Duragesic Trials Continue Plaintiffs Optimistic After Latest Recall 11870 1 Duragesic Trials Continue Plaintiffs Optimistic After Latest Recall 11870 2 Cancer Drug Works Against MS in Early Trial 11869 1 Cancer Drug Works Against MS in Early Trial 11869 2 Cancer Drug Works Against MS in Early Trial 11869 3 Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results 3275 1

[1] Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment [0] Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab [0] Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders [0] Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring?

...wire-FirstCall/ -- Vical,Incorporated today announ...ith the company,s Vaxfectin(TM) adjuvant generated...nformulated vaccine,at the same dose in a recently...steur,s Fluzone(R) commercial vaccine with,Vaxfect...vaccine,dose while generating equivalent or better...

...Apr 10, 2007 - Valeant,Pharmaceuticals Internation...hase 2 data for retigabine, a first-in-class,neuro...ing,independent, scientific journal. The authors c...monstrated reduction in monthly,seizure rates in t...d RESTORE2) are currently underway to further inve...

Other Medicine Technology:Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 2 Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 3 Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 4 Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 5 Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2 Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3

Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology